Thanks for sharing Prestonian.. 1. Agree some ex-Sun Biomedical...

Thanks for sharing Prestonian..

1. Agree some ex-Sun Biomedical holders may have sold out since the RTO. The largest SBN holder was Jason Peterson and he recently has sold down his entire holding- which has added to significant supply in recent times.. This is now done.

2. Agree in part that the fact that safety and efficacy hasn't been definitively been demonstrated , given this is the first clinical study, has limited the share price. However, we should keep a few things in mind here- the two compounds are registered and approved drugs! No need to show safety as individual drugs in the dosages used.. This is a huge advantage- better than any other new drug that has shown safety in ph2 or even ph3 trials. The combo mechanistically should be safe, but agree this needs to be shown. Having said that, in my experience the ASX biotech punters don't pay much of a premium for showing safety.. They only want to see efficacy. Also- pls note you won't see any real efficacy in Ph1 studies.

If you look at ACW - it has a market cap of closer to $40M with only phase 1 safety data.. Ph2a just started.. Innate was buoyed by encouraging outcomes with their NZ patients obtaining the drug under compassionate access schemes and positive messaging from the Compamy throughout the study , but that obviously didn't turn out well. PBT really only had safety demonstrated before its ph2b bombed.. Not before a huge rise in the stock price. And then there's little old DXB.. Got a great basis to be safe, has shown in a small sample of 11 patients that it can be extremely effective treating proteinuria in some patients already.. So one would expect it to be trading higher than it is..

So why is the price so low relative to others.. Who knows , maybe..

SBN overhang. Ridiculously low CR at 0.6c in Jan has limited the recent SP gains. Limited broker support. No institutional support (too much for most instos, but wouldn't mind an AEF on board), Lack of strong East Coast support base and awareness. Technology is too complex for most and has until recently been poorly communicated by management. Market value proposition with DMx-200 and CKD /FSGS has been undersold. Business model undersold (licensing opportunities). Overly scientific and conservative approach in communications from the Company to date- much improved now. Other than James Williams- unknown Board. Hugh helps. A decent scientific advisory Board would help too.

Seems like a lot of the above are either being proactively fixed by the Company or are naturally resolving.. So with upcoming results, greater awareness, higher profile board and better corporate messaging- it seems the fun will start after the results rather than before as has been the case with a number of its peers..

All the best guys.. Whatever your strategy is with DXB!

A.